Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.

Pharmacoeconomics · 2017 · PMC5253156 · PMID 27566699

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

According to the company, the Independent Data Monitoring Committee for the COU-AA-302 trial concluded on 27 February 2012 that patients in the AAP arm had a ‘highly significant advantage’, even though the HR for OS had not reached the stringent prespecified statistical significance level (0.0034).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.